About Us

ChemGenex Pharmaceuticals Ltd, an integrated biopharmaceutical development company, engages in the discovery and the development of oncology drugs. The company's product candidates include omacetaxine mepesuccinate, an investigational small molecule agent that is in Phase 2/3 clinical trial for the treatment of chronic myelogenous leukemia, and is also in Phase 2 clinical trials for the treatment of acute myelogenous leukemia and myelodysplastic syndrome; and Quinamed, which is in Phase 2 clinical trial for the treatment of hormone refractory prostate cancer. It was formerly known as AGT Biosciences Limited and changed its name to ChemGenex Pharmaceuticals Ltd in June 2004. The company was founded in 1958 and is headquartered in Geelong, Australia.


Business size

1-10 employees


Commercial presence